Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)

June 2, 2026 6:58 AM EDT Send to a Friend
H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $105.00 price target on Monopar Therapeutics (NASDAQ: MNPR).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login